BALTIMORE--(BUSINESS WIRE)--CraniUS™, an R&D company focused on groundbreaking diagnostics and treatments for patients with chronic brain disease, has been awarded a competitive $1 million grant from the State of Maryland as part of Governor Wes Moore’s Build Our Future Innovation Infrastructure Pilot Program. This funding milestone – the first ever granted by the state program - will help CraniUS™ expand its research capabilities, accelerate product development into human studies, and enhance its contributions to Maryland’s innovation ecosystem.
Governor Moore officially launched the Build Our Future program, a $9 million initiative designed to support transformative projects across Maryland’s strategic industry sectors, in 2023 and announced the recipients of this first pilot funding round earlier this week. The program provides matching grants of up to $2 million to projects that demonstrate a substantial impact on growth and innovation within the state.
CraniUS™’s groundbreaking work in skull-embedded neurotechnology aims to revolutionize treatments for neurological disorders by pioneering a new frontier: the brain-medicine interface (BMI), creating an expansive new platform in neurological medicines that can be delivered safely and directly to the brain to treat multiple diseases. Its patented flagship device, the NeuroPASS™, is being specifically developed to bypass the challenges presented by the blood-brain barrier, which has rendered traditional therapeutic treatments of brain disease ineffective.
"We are thrilled and grateful to receive this support from the State of Maryland," said Mike Maglin, CEO of CraniUS™. "This grant is not just a recognition of our groundbreaking work, but a testament to the state’s commitment to fostering innovation and supporting high-impact projects. With this funding, we are poised to make significant strides in our mission to develop life-changing neurotechnology solutions."
About CraniUS™
CraniUS™ was founded May 2021 in Baltimore, MD, as a byproduct of the emerging field known as "Neuroplastic and Reconstructive Surgery", through the vision, insight, and pioneering work of Dr. Chad Gordon. CraniUS™ has raised over $24M to date, been issued 7 patents, and is currently in the midst of a Series B raise.
The NeuroPASS™ device is currently in the pre-clinical development stage and is not yet commercially available. It is on the pathway to clinical studies, and any information provided is subject to change as research progresses.
Contacts
CraniUS™ Media Relations
1(833) 4-CraniUS
This email address is being protected from spambots. You need JavaScript enabled to view it.
https://craniusmed.com